Hepatitis C Virus (HCV) RNA, Quantitative, Real-time PCR

Hepatitis C Virus (HCV) RNA, Quantitative, Real-time PCR—also referred to as HCV viral load or HCV RNA quant—confirms current infection by demonstrating replicating virus and provides a quantitative baseline for disease assessment. In conjunction with HCV genotype, viral load assists with prognostic assessment. This assay is used to monitor antiviral therapy by characterizing early on‑treatment declines in HCV RNA and by determining whether HCV RNA becomes undetectable at the end of therapy and after treatment has concluded.

HCV is an enveloped RNA virus in the Flaviviridae family with primary tropism for hepatocytes. Extrahepatic replication occurs in circulating cells, including neutrophils, monocytes/macrophages, and B lymphocytes, and infection is linked to mixed cryoglobulinemia, Sjögren syndrome, and B‑cell lymphoproliferative disorders. A high mutation rate promotes immune evasion. Six major genotypes and multiple subtypes differ in therapeutic responsiveness and prognostic implications. Transmission is predominantly parenteral through exposure to blood products, transplanted organs, or nonsterile needles and instruments (eg, tattooing, piercing); sexual and perinatal transmission occur but are less frequent. Acute infection is often silent; only about 15% develop an acute illness with symptoms such as nausea, myalgias, anorexia, or weight loss, and jaundice is uncommon. Chronic infection develops in 60%–85% of those infected and is typically accompanied by mild aminotransferase elevations with few or no symptoms. Among chronically infected individuals, cirrhosis emerges in 20%–30% and confers heightened risks of hepatic failure and hepatocellular carcinoma. Detection of HCV RNA indicates active viral replication and establishes the diagnosis of current infection. RNA becomes detectable by PCR approximately 10–12 days after exposure, preceding seroconversion and often biochemical abnormalities. PCR methods may be qualitative or quantitative: qualitative assays verify the presence of replicating virus, whereas quantitative assays provide viral load data used for treatment monitoring and prognostication. Effective therapy is usually associated with a decline of ≥2 log10 in viral load within 4–12 weeks and eventual undetectable HCV RNA at end of treatment; lack of an early decline suggests nonresponse. Testing is recommended before therapy begins, at on‑treatment milestones (eg, weeks 4, 12, and 24), and after therapy; specific schedules vary by genotype and disease severity.